[go: up one dir, main page]

DK1268530T3 - Hepatitis B-kerneantigen-fusionsproteiner - Google Patents

Hepatitis B-kerneantigen-fusionsproteiner

Info

Publication number
DK1268530T3
DK1268530T3 DK01919645T DK01919645T DK1268530T3 DK 1268530 T3 DK1268530 T3 DK 1268530T3 DK 01919645 T DK01919645 T DK 01919645T DK 01919645 T DK01919645 T DK 01919645T DK 1268530 T3 DK1268530 T3 DK 1268530T3
Authority
DK
Denmark
Prior art keywords
particles
loop
hbcag
sequences
core
Prior art date
Application number
DK01919645T
Other languages
English (en)
Inventor
A Gehin
R Gilbert
D Stuart
D Rowlands
Original Assignee
Univ Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leeds filed Critical Univ Leeds
Application granted granted Critical
Publication of DK1268530T3 publication Critical patent/DK1268530T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/02Hepadnaviridae, e.g. hepatitis B virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01919645T 2000-04-07 2001-04-09 Hepatitis B-kerneantigen-fusionsproteiner DK1268530T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00107118 2000-04-07

Publications (1)

Publication Number Publication Date
DK1268530T3 true DK1268530T3 (da) 2006-11-13

Family

ID=8168351

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01919645T DK1268530T3 (da) 2000-04-07 2001-04-09 Hepatitis B-kerneantigen-fusionsproteiner

Country Status (18)

Country Link
US (1) US7270821B2 (da)
EP (1) EP1268530B1 (da)
JP (1) JP4713809B2 (da)
KR (1) KR100808313B1 (da)
CN (1) CN100360556C (da)
AP (1) AP1836A (da)
AT (1) ATE336502T1 (da)
AU (1) AU784345B2 (da)
BR (1) BR0109919A (da)
CA (1) CA2405438C (da)
DE (1) DE60122300T2 (da)
DK (1) DK1268530T3 (da)
EA (1) EA200201077A1 (da)
ES (1) ES2269371T3 (da)
MX (1) MXPA02009895A (da)
PT (1) PT1268530E (da)
WO (1) WO2001077158A1 (da)
ZA (1) ZA200208967B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1218514B1 (en) * 1999-10-08 2006-04-26 Celltech Pharma Europe Limited Designing immunogens
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
ATE447967T1 (de) 2001-09-14 2009-11-15 Cytos Biotechnology Ag Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
KR100465643B1 (ko) * 2001-09-28 2005-01-13 (주) 에이프로젠 비형 간염 바이러스 프리에쓰1 항원 유래의 에피토프 태그및 이에 대한 항체를 이용한 폴리펩티드의 검출 및 정제방법
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
MXPA04002644A (es) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Conjugados que portan un peptido de angiotensina y usos de los mismos.
IL165249A0 (en) 2002-07-18 2005-12-18 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
EP1524994B1 (en) 2002-07-19 2011-04-27 Cytos Biotechnology AG Vaccine compositions containing amyloid beta1-6 antigen arrays
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US7517520B2 (en) 2003-03-26 2009-04-14 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
CN100537762C (zh) * 2004-06-24 2009-09-09 中国人民解放军军事医学科学院野战输血研究所 一种嵌合型病毒样颗粒疫苗载体蛋白及其制备方法与应用
KR100687653B1 (ko) * 2005-05-13 2007-02-27 유기현 스타-델타 결선용 전자개폐기의 제어방법
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
JP5209800B2 (ja) 2008-12-09 2013-06-12 ファイザー バクシーンズ エルエルシー IgECH3ペプチドワクチン
PE20120817A1 (es) 2009-07-30 2012-07-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos
JP2013503623A (ja) 2009-09-03 2013-02-04 ファイザー バクシーンズ エルエルシー Pcsk9ワクチン
GB0918679D0 (en) * 2009-10-23 2009-12-09 Iqur Ltd Influenza vaccine
EP2547695B1 (en) * 2010-03-16 2018-05-09 Biontech Protein Therapeutics GmbH Tumor vaccination involving a humoral immune response against self-protein cldn18.2
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
CN102199217B (zh) * 2011-04-01 2013-03-27 中国人民解放军第三军医大学 乙型肝炎病毒多表位融合蛋白及其制备方法和应用
KR20140048119A (ko) 2011-04-15 2014-04-23 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Dna 백신
KR102205077B1 (ko) 2012-08-31 2021-01-20 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Vegf-특이적 에피토프 및/또는 안지오포이에틴-2-특이적 에피토프를 함유하는 dna 백신
CA2893120C (en) * 2012-12-11 2022-03-15 Imaxio Modified coiled coil type proteins having improved properties
US20160122420A1 (en) * 2013-06-06 2016-05-05 Rowlands David J Antibody display
CN104341506A (zh) * 2013-07-30 2015-02-11 复旦大学 一种重组融合蛋白及其用途
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
GB201402890D0 (en) * 2014-02-18 2014-04-02 Iqur Ltd Vaccines based on hepatitis B Core antigens
GB201421692D0 (en) * 2014-12-05 2015-01-21 Iquar Ltd Vaccines based on hepatitis B core antigens
GB201505041D0 (en) * 2015-03-25 2015-05-06 Iqur Ltd Vaccines based on hepatitis B core antigens
EP3538147A4 (en) * 2016-11-11 2020-07-08 Fraunhofer USA, Inc. COVALENT FUSIONED VIRAL ENVELOPES FOR DISPLAYING TARGET MOLECULES
EP3781689A1 (en) 2018-04-19 2021-02-24 Checkmate Pharmaceuticals, Inc. Synthetic rig-i-like receptor agonists
CN110343707B (zh) * 2019-05-30 2021-06-15 中国科学院生物物理研究所 基于乙肝核心抗原的hsv分型用蛋白、试剂盒及方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480780B1 (fr) * 1980-04-22 1985-12-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
JP2514033B2 (ja) * 1987-05-20 1996-07-10 財団法人 癌研究会 B型肝炎ウィルスの複製を可能とする新規な培養細胞
NZ235315A (en) * 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
US5723129A (en) * 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
JPH06279500A (ja) * 1992-09-30 1994-10-04 Imuno Japan:Kk HBc融合蛋白粒子およびその製造方法
AU2540897A (en) * 1996-03-21 1997-10-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chimeric polypeptides for tumor antigen vaccines
US20030021804A1 (en) * 1997-01-21 2003-01-30 Philip Needleman Immunological process for increasing the hdl cholestrol concentration
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6180343B1 (en) * 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
EP1218514B1 (en) * 1999-10-08 2006-04-26 Celltech Pharma Europe Limited Designing immunogens
ATE320493T1 (de) * 2000-06-22 2006-04-15 Ucb Pharma Ltd Modifizierung des hepatitis b kernantigens
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis

Also Published As

Publication number Publication date
CA2405438A1 (en) 2001-10-18
KR20030009429A (ko) 2003-01-29
PT1268530E (pt) 2006-12-29
US20040223965A1 (en) 2004-11-11
US7270821B2 (en) 2007-09-18
AP2002002658A0 (en) 2002-12-31
ZA200208967B (en) 2003-10-08
AU4670601A (en) 2001-10-23
CN1441807A (zh) 2003-09-10
ES2269371T3 (es) 2007-04-01
EA200201077A1 (ru) 2003-04-24
ATE336502T1 (de) 2006-09-15
JP2003530123A (ja) 2003-10-14
KR100808313B1 (ko) 2008-02-27
EP1268530B1 (en) 2006-08-16
BR0109919A (pt) 2003-03-11
MXPA02009895A (es) 2004-09-06
WO2001077158A1 (en) 2001-10-18
CA2405438C (en) 2011-07-12
CN100360556C (zh) 2008-01-09
AP1836A (en) 2008-03-14
DE60122300D1 (de) 2006-09-28
AU784345B2 (en) 2006-03-16
DE60122300T2 (de) 2007-08-30
JP4713809B2 (ja) 2011-06-29
EP1268530A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
DK1268530T3 (da) Hepatitis B-kerneantigen-fusionsproteiner
Singh et al. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice
Netter et al. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes
EA200100619A1 (ru) Коровые антигенные частицы hbv с множественными иммуногенными компонентами, связанными посредством пептидных лигандов
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
DK0755259T3 (da) Kimære-cDNA-kloner af virussen for den infektiöse GUMBORO-syge, ekspressionsprodukter heraf og vacciner baseret derpå
ATE125821T1 (de) Vakzin gegen hepatitis b.
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
EP1013757A3 (en) Attenuated forms of bovine viral diarrhea virus
CN1874787B (zh) 预防/治疗hbv感染和hbv介导疾病的组合物
Murray Application of recombinant DNA techniques in the development of viral vaccines
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
Dreesman et al. Immunization of chimpanzees with hepatitis B virus-derived polypeptides
Ellis et al. Recombinant hepatitis B vaccines
CA1292690C (en) Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic sequentially homologous peptide
ATE312846T1 (de) Monoklonale antikörper gegen hepatitis b virus
WO1986001826A1 (en) Hepatitis a virus purified and triply cloned
YU45292A (sh) Različiti površinski proteini hepatitis b virusa koji obrazuju čestice
Iwarson New approaches to hepatitis A and B vaccines
Michel DNA-mediated immunization: prospects for hepatitis B vaccination
Deinhardt et al. Vaccines against hepatitis
FR2760458B1 (fr) Peptide structural antigenique, composes antigenique et immunogene et utilisations dans la detection, la prevention et le traitement d'une infection par le vhc
DE69814884D1 (de) Hepatitis b virale polypeptide
BEESLEY EXPRESSION OF HBCAG FUSION PROTEINS IN YEAST AND AN INVESTIGATION OF THEIR IMMUNOLOGICAL PROPERTIES (IMMUNOLOGY)